Valuation: Morepen Laboratories Limited

Market Cap 49.59B 531M 482M 445M 402M 758M 787M 5.36B 2.12B 26.76B 1.99B 1.95B 84.55B P/E 2025
21.8x
P/E 2026 19.5x
Enterprise Value 51.13B 547M 497M 459M 414M 782M 811M 5.53B 2.19B 27.59B 2.05B 2.01B 87.17B EV / Sales 2025
1.45x
EV / Sales 2026 1.11x
Free-Float
57.95%
Yield 2025
0.42%
Yield 2026 0.59%
1 week-6.41%
Current month-20.40%
1 month-25.73%
3 months+2.42%
6 months+118.97%
Current year+120.36%
1 week 88.15
Extreme 88.15
102
1 month 88.1
Extreme 88.1
132.7
Current year 33.44
Extreme 33.44
150.8
1 year 33.44
Extreme 33.44
150.8
3 years 33.44
Extreme 33.44
150.8
5 years 23.65
Extreme 23.65
150.8
10 years 7.21
Extreme 7.21
150.8
Manager TitleAgeSince
Chief Executive Officer 58 30/06/2026
Chief Executive Officer 62 31/01/1992
Director of Finance/CFO 59 02/04/2002
Director TitleAgeSince
Chairman 62 31/01/1992
Director/Board Member 58 12/08/2019
Director/Board Member 58 12/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%-6.41%+97.86%+128.25% 553M
-1.13%-1.17%+38.55%+139.23% 1,275B
-1.36%-0.74%+39.64%+86.06% 680B
-0.59%-0.36%+25.14%+111.73% 521B
-0.76%+1.10%+41.43%+70.96% 389B
-0.75%-3.16%+54.39%+40.90% 356B
-1.83%-0.89%+26.00%+58.48% 305B
-1.65%-0.59%+1.55%+34.52% 287B
-0.95%-1.57%+34.01%+72.55% 250B
+1.60%-0.36%+37.21%+125.66% 208B
Average -0.74%-0.76%+39.58%+86.83% 427B
Weighted average by Cap. -0.98%-0.55%+34.97%+95.63%

Financials

2025 2026
Net sales 18.12B 194M 176M 163M 147M 277M 288M 1.96B 775M 9.78B 727M 712M 30.89B 18.06B 193M 175M 162M 146M 276M 287M 1.95B 772M 9.74B 725M 710M 30.79B
Net income 1.18B 12.63M 11.47M 10.59M 9.56M 18.04M 18.73M 128M 50.49M 637M 47.39M 46.4M 2.01B 949M 10.15M 9.22M 8.52M 7.68M 14.5M 15.06M 103M 40.59M 512M 38.1M 37.3M 1.62B
Net Debt -928K -9.93K -9.02K -8.33K -7.51K -14.19K -14.73K -100K -39.7K -501K -37.27K -36.48K -1.58M 1.54B 16.46M 14.94M 13.8M 12.45M 23.51M 24.41M 166M 65.79M 830M 61.76M 60.46M 2.62B
Projected Income Statement - Annual - Morepen Laboratories Limited
Logo Morepen Laboratories Limited
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Employees
1,919
Date Price Change Volume
18/11/26 ₹90.05 -0.50% 134,200
17/11/26 ₹90.50 -4.54% 370,626
16/11/26 ₹94.80 -4.96% 344,087
13/11/26 ₹99.75 +5.00% 609,884
12/11/26 ₹95.00 -1.76% 252,559
  1. Stock Market
  2. Stocks
  3. MOREPENLAB Stock